Lynx1 Capital Management Lp
- Regulatory AUM
- $627M
- Discretionary
- $627M
- Clients
- 5
- Avg AUM / client
- $125M
- Accounts
- 5
- Employees
- 5
AUM over time
Reported AUM from Form ADV filings, plotted by filing date · as of Mar 31, 2026
Investments (13F portfolio — 23 positions, $632,718,355)
13F period Mar 31, 2026| # | Issuer | Class | Value | Shares | % of 13F | % of AUM |
|---|---|---|---|---|---|---|
| 1 | Stoke Therapeutics Inc | COM | $155,105,193 | 4,763,673 | 24.5% | 24.8% |
| 2 | Gh Research Plc | ORDINARY SHARES | $151,331,829 | 10,763,288 | 23.9% | 24.1% |
| 3 | Cullinan Therapeutics Inc | COM | $127,371,335 | 8,963,500 | 20.1% | 20.3% |
| 4 | Agios Pharmaceuticals Inc | COM | $88,349,345 | 2,611,568 | 14.0% | 14.1% |
| 5 | Denali Therapeutics Inc | COM | $36,101,818 | 1,880,303 | 5.71% | 5.76% |
| 6 | C4 Therapeutics Inc | COM STK | $18,407,112 | 6,998,902 | 2.91% | 2.94% |
| 7 | Korro Bio Inc | COM | $17,413,511 | 1,538,296 | 2.75% | 2.78% |
| 8 | Tscan Therapeutics Inc | COM | $8,099,339 | 8,019,148 | 1.28% | 1.29% |
| 9 | Xencor Inc | COM | $6,468,960 | 536,398 | 1.02% | 1.03% |
| 10 | Precision Biosciences Inc | COM NEW | $5,418,122 | 985,113 | 0.86% | 0.86% |
| 11 | Passage Bio Inc | COM NEW | $4,896,076 | 623,704 | 0.77% | 0.78% |
| 12 | Neuphoria Therapeutics Inc | COM | $3,562,585 | 875,328 | 0.56% | 0.57% |
| 13 | Entrada Therapeutics Inc | COM | $2,671,515 | 211,689 | 0.42% | 0.43% |
| 14 | Cg Oncology Inc | COM | $2,138,079 | 31,591 | 0.34% | 0.34% |
| 15 | Immatics N.V | SHS | $2,135,014 | 216,973 | 0.34% | 0.34% |
| 16 | Design Therapeutics Inc | COM | $1,271,650 | 119,516 | 0.2% | 0.2% |
| 17 | Vyne Therapeutics Inc | COM | $973,148 | 1,628,700 | 0.15% | 0.16% |
| 18 | Werewolf Therapeutics Inc | COM | $547,673 | 657,786 | 0.09% | 0.09% |
| 19 | Ibio Inc | COM NEW | $129,344 | 68,076 | 0.02% | 0.02% |
| 20 | Bolt Biotherapeutics Inc | COM NEW | $124,432 | 30,800 | 0.02% | 0.02% |
| 21 | Proqr Thrapeutics N V | SHS EURO | $110,947 | 68,486 | 0.02% | 0.02% |
| 22 | Absci Corporation | COM | $63,735 | 21,245 | 0.01% | 0.01% |
| 23 | Traws Pharma Inc | COM NEW | $27,593 | 15,078 | 0.0% | 0.0% |
Top 25 of 23 positions from the manager's latest Form 13F · source filing (EDGAR) ↗. 13F covers long US-listed positions only. "% of AUM" is share of the firm's total regulatory AUM (Form ADV Item 5.F).
Who they serve
| Client type | Clients | AUM | % of AUM |
|---|---|---|---|
| Pooled investment vehicles (non-investment companies) | 5 | $627M | 100.0% |
Private funds (2)
Reported in Form ADV Section 7.B.(1), filing of Aug 2024 · $239M combined gross assets
| Fund | Type | Domicile | Gross assets | Owners |
|---|---|---|---|---|
| Lynx1 Master Fund Lp master | Hedge Fund | Cayman Islands | $239M | 10 |
| Lynx1 Opportunity Fund I Lp | Private Equity Fund | Delaware | $67.0K | 18 |
People (2)
| Name | Role / title | Credentials | With firm since | Ownership |
|---|---|---|---|---|
| Nichols, Weston, Agnew | Chief Investment Officer, Limited Partner | May 2020 (6y) | 75% or more | |
| Partyka Zamora, Nathali, Joaquina | Chief Compliance Officer | Jul 2024 (2y) | Less than 5% |
Entity owners (Schedule A/B)
| Entity | Title / status | Since | Sch. | Ownership |
|---|---|---|---|---|
| Lynx1 Capital Management Gp Llc | General Partner | May 2020 | A | Less than 5% |
Undisclosed: 0% – 25% of the firm is not attributable from the filed Schedule A bands.
Roster from the IAPD representatives feed; ownership and acquisition dates from Form ADV Schedule A/B. "Since" is the earliest filed registration or acquisition date.
Private funds (2, $239M gross assets)
| Fund | Type | Gross assets | Min. investment | Owners |
|---|---|---|---|---|
| Lynx1 Master Fund Lp | Hedge Fund | $239M | $5.0M | 10 |
| Lynx1 Opportunity Fund I Lp | Private Equity Fund | $67.0K | $0 | 18 |
From Form ADV Section 7.B private fund reporting.
Documents (1 archived)
| Form | Period | Size | |
|---|---|---|---|
| Form ADV (full filing) | 03/31/2026 | 1.52 MB | View · PDF · Source ↗ |
Archived copies of the firm's regulatory filings, versioned by content hash.
Disciplinary disclosures
No disciplinary events reported on the firm's latest Form ADV filing.
How they charge
- • Percentage of assets under management
- • Performance-based fees
Services
- • Portfolio management for pooled investment vehicles
Custody
Firm reports having custody of client funds or securities (Item 9.A).
No custodian data reported or mined yet.
Source
All data on this page comes from this firm's Form ADV filings, reproduced without modification. Latest filing: Mar 31, 2026.
View current Form ADV (SEC/IAPD) ↗